Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives.
BACKGROUND
Axitinib is a next-generation, selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors. It is approved for the treatment of metastatic renal cell carcinoma (mRCC) based on a demonstrated progression-free survival advantage over sorafenib in the second-line treatment setting. However, given the variety of available targeted therapies for mRCC, appropriate patient selection for the available therapies remains a significant clinical challenge.


OBJECTIVE
This review summarizes the available evidence on the clinical, toxicity, and pharmacologic considerations for determining appropriate patient selection for axitinib therapy. In addition, it describes recent data on the use of predictive biomarkers to guide clinical management. This paper consists of material obtained via PubMed and Medline literature searches through October 2015.


CONCLUSIONS
Axitinib has a well-established role in the management of mRCC. Consistent clinical efficacy has been demonstrated across prognostic risk groups and prior therapeutic exposures. Although axitinib is generally well tolerated, appropriate toxicity management is critical to maximizing drug delivery and optimizing treatment outcomes. Although incident hypertension has been associated with improved clinical outcomes on axitinib, there are currently no validated clinical or genetic predictive biomarkers to guide patient selection.
Division of Hematology/Medical Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Vivek
V
Narayan
Division of Hematology/Medical Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Naomi Balzer
NB
Haas
axitinib; predictive marker; renal cell carcinoma; vascular endothelial growth factor receptor